Gut microbiota: an Indicator to Gastrointestinal Tract Diseases

Journal of Gastrointestinal Cancer

Volumn 47, Issue 3, 2016, Pages 232-238

  Patel, Trupti ^a   Bhattacharya, Priyanjali ^a   Das, Suvrajit ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Gastric cancer; Gastrointestinal tract; Gut microbiota; Inflammatory bowel disease; Oesophagus

Indexed keywords

ANIMAL; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE FLORA; MICROBIOLOGY;

ANIMALS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; HUMANS;

EID: 84964412432     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-016-9820-x     Document Type: Review

References (67)

1. Ley RE, Hamady M, Lozupone C, Turnbaugh P, Ramey RR, Bircher JS, et al. Evolution of mammals and their gut microbes. Science. 2008;320:1647–51.
2. Qin J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.
3. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148:1258–70.
4. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587:4153–8.
5. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904.
6. Cryan JF, O’Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011;23:187–92.
7. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–14.
8. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688–93.
9. Adlerberth I, Wold AE. Establishment of the gut microbiota in Western infants. Acta Paediatr. 2009;98:229–38.
10. Claesson MJ, Jeffery IB, Stanton C, Ross RP, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488:178–84. doi:10.1038/nature11319.
11. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5:e177.
12. Claesson MJ et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4586–91.
13. Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev. 2007;65:S173–6.
14. Gagliardi D, Makihara S, Corsi PR, Viana Ade T, Wiczer MV, Nakakubo S, et al. Microbial flora of the normal esophagus. Dis Esophagus. 1998;11:248–50.
15. Pajecki D, Zilberstein B, dos Santos MA, Ubriaco JA, Quintanilha AG, Cecconello I, et al. Megaesophagus microbiota: qualitative and quantitative analysis. J Gastrointest Surg. 2002;6:723–9.
16. Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ. Bacterial biota in the human distal esophagus. Proc Natl Acad Sci U S A. 2004;101:4250–5.
17. Suerbaum S. Microbiome analysis in the esophagus. Gastroenterology. 2009;137:419–21.
18. Macfarlane S, Furrie E, Macfarlane GT, Dillon JF. Microbial colonization of the upper gastrointestinal tract in patient s with Barrett’s esophagus. Clin Infect Dis. 2007;45:29–38.
19. Norder Grusell E, Dahlén G, Ruth M, Ny L, Quiding­Järbrink M, Bergquist H, et al. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus. 2013;26:84–90.
20. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137:588–97.
21. Pei Z, Yang L, Peek RM, Levine Jr SM, Pride DT, Blaser MJ. Bacterial biota in reflux esophagitis and Barrett’s esophagus. World J Gastroenterol. 2005;11:7277–83.
22. Loftus E Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.
23. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599–608.
24. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser A, Barnich N et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127:412–21.
25. Collins D, Hogan AM, Winter DC. Microbial and viral pathogens in colorectal cancer. Lancet Oncol. 2011;12:504–12.
26. Tlaskalová­Hogenová H, Stepánková R, Kozáková H, Hudcovic T, Vannucci L, Tucková L, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in thepathogenesis of inflammatory and autoimmune diseases and cancer:contribution of germ­free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8:110–20.
27. Scanlan PD, Shanahan F, Clune Y, Collins JK, O’Sullivan GC, O’Riordan M, et al. Culture­independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol. 2008;10(3):789–98.
28. Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes. 2010;1:138–47.
29. Cotter PD. Small intestine and microbiota. Curr Opin Gastroenterol. 2011;27:99–105.
30. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011;9:461–9. quiz e59.
31. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–8.
32. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double­ blind, randomized, placebo­ controlled study. Am J Gastroenterol. 2003;98:412–9.
33. Blackett KL, Siddhi SS, Cleary S, Steed H, Miller MH, Macfarlane S, et al. Oesophageal bacterial biofilm changes in gastrooesophageal reflux disease, Barrett’s and oesophageal carcinoma: association or causality? Aliment Pharmacol Ther. 2013;37:1084–92.
34. Dicksved J, Lindberg M, Rosenquist M, Enroth H, Jansson JK, Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol. 2009;58:509–16.
35. Engstrand L, Lindberg M. Helicobacter pylori and the gastric microbiota. Best Pract Res Clin Gastroenterol. 2013;27:39–45.
36. Piscaglia AC, Campanale M, Gasbarrini G. Small bowel nonendocrine neoplasms: current concepts and novel perspectives. Eur Rev Med Pharmacol Sci. 2010;14:320–6.
37. Pagnini C, Corleto VD, Mangoni ML, Pilozzi E, Torre MS, Marchese R, et al. Alteration of local microflora and a defensins hyper-production in colonic adenoma mucosa. J Clin Gastroenterol. 2011;45:602–10.
38. Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, Boleij A, et al. Towards the human colorectal cancer microbiome. PLoS One. 2011;6:e20447.
39. Yang L, Pei Z. Bacteria, inflammation, and colon cancer. World J Gastroenterol. 2006;12(42):6741–6.
40. Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1298–303.
41. Ohara T, Yoshino K, Kitajima M. Pre- and probiotics increase host-cell immunological competence, improve bowel movement, and prevent the onset of colon cancer—an analysis based on movements of intestinal microbiota. Rinsho Byori. 2009;57(6):533–41.
42. Kostic AD et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8.
43. Kostic AD et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207–15.
44. Arthur JC et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120–3.
45. Boleij A, Roelofs R, Schaeps RM, et al. Increased exposure to bacterial antigen RpL7/L12 in early stage colorectal cancer patients. Cancer. 2010;116(17):4014–22.
46. O’Keefe SJ, Ou J, Aufreiter S, et al. Products of the colonic microbiota mediate the effects of diet on colon cancer risk. J Nutr. 2009;139(11):2044–8.
47. Kawano A, Ishikawa H, Nakamura T, Kono K. Evaluation of epidemiological studies of intestinal bacteria that affected occurrence of colorectal cancer: studies of prevention of colorectal tumors by dairy products and lactic acid bacteria. Nippon Eiseigaku Zasshi. 2010;65(3):422–46.
48. Kumar M, Kumar A, Nagpal R, et al. Cancer-preventing attributes of probiotics: an update. Int J Food Sci Nutr. 2010;61(5):473–96.
49. Duttona RJ, Turnbaugh PJ. Taking a metagenomic view of human nutrition. Curr Opin Clin Nutr Metab Care. 2012;15:448–54.
50. Macdonald RS, Wagner K. Influence of dietary phytochemicals and microbiota on colon cancer. J Agric Food Chem. 2012;60:6728–35.
51. Sengottuvelan M, Nalini N. Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2 dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr. 2006;96(1):145–53.
52. Namasivayam N. Chemoprevention in experimental animals. Ann N Y Acad Sci. 2011;1215:60–71.
53. Losso JN, Bansode RR, Trappey 2nd A, Bawadi HA, Truax R. In vitro antiproliferative activities of ellagic acid. J Nutr Biochem. 2004;15(11):672–8.
54. Tulipani S, Urpi-Sarda M, García-Villalba R, Rabassa M, López-Uriarte P, Bullo M, et al. Urolithins are the main urinary microbial-derived phenolic metabolites discriminating a moderate consumption of nuts in free-living subjects with diagnosed metabolic syndrome. J Agric Food Chem. 2012;60(36):8930–40.
55. Miene C, Weise A, Glei M. Impact of polyphenol metabolites produced by colonic microbiota on expression of COX-2 and GSTT2 in human colon cells (LT97). Nutr Cancer. 2011;63(4):653–62.
56. Kang NJ, Lee KW, Kim BH, Bode AM, Lee HJ, Heo YS, et al. Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. Carcinogenesis. 2011;32:921–8.
57. Butt MS, Sultan MT. Green tea: nature’s defense against malignancies. Crit Rev Food Sci Nutr. 2009;49:463–73.
58. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82(12):1807–21.
59. Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med. 2011. doi:10.1093/ecam/meq053.
60. Tzounis X, Rodriguez-Mateos A, Vulevic J, Gibson GR, Kwik-Uribe C, Spencer JP. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr. 2011;93(1):62–72.
61. Beloborodova N, Bairamov I, Olenin A, Shubina V, Teplova V, Fedotcheva N. Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils. J Biomed Sci. 2012;19:89.
62. Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, et al. Interactions between commensal fungi and the C­type l ectin receptor Dectin­1 influence colitis. Science. 2012;336:1314–7.
63. Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature. 2010;466:334–8.
64. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107:14691–6.
65. Jakobsson HE, Jernberg C, Andersson AF, Sjölund­Karlsson M, Jansson JK, Engstrand L. Short­term antibiotic treatment has differing long­term impacts on the human throat and gut microbiome. PLoS One. 2010;5:e9836.
66. Sartor RB. Gut microbiota: diet promotes dysbiosis and colitis in susceptible hosts. Nat Rev Gastroenterol Hepatol. 2012;9:561–2.
67. Aron­Wisnewsky J, Doré J, Clement K. The importance of the gutmicrobiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012;9:590–8.